Stock AEZS AETERNA ZENTARIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Aeterna Zentaris Inc.

Equities

AEZS

CA0079756007

End-of-day quote Toronto S.E.
Other stock markets
 06:00:00 2024-05-16 pm EDT 		5-day change 1st Jan Change
11.57 CAD +0.17% Intraday chart for Aeterna Zentaris Inc. +4.33% +12.55%
May. 17 Aeterna Zentaris Finalizes Some Details for Ceapro Merger MT
May. 17 Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aeterna Zentaris Finalizes Some Details for Ceapro Merger
MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro
MT
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
AQ
Aeterna Zentaris : Condensed Interim Consolidated Financial Statements As of March 31, 2024, and for the three months ended March 31, 2024, and 2023 - Form 6-K
PU
Aeterna Zentaris : Audited Consolidated Financial Statements of Ceapro Inc. as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022 - Form 6-K
PU
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden
MT
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Aeterna Zentaris Reports First Quarter 2024 Financial Results
AQ
Aeterna Zentaris : MATERIAL CHANGE REPORT - Form 6-K
PU
Reverse Split: 1 of 4
FA
Aeterna Zentaris Announces Effective Date of Share Consolidation
AQ
North American Morning Briefing : Powell Awaited -2-
DJ
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions
MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris
MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update
MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency
MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share
MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
AQ
Aeterna Zentaris : Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AEZS Stock
  4. News Aeterna Zentaris Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW